Immunicum is featured on Swedish national TV on SVT1. See the feature here.

The company is also presented in DN. Read the article here.

The Medical Products Agency approves Immunicum's application to start a clinical phase I/II trial (EudraCT-nr 2011-002039-25) in renal cell carcinoma. The trial is expected to commence in Q1 2012.

Read the news in Nyteknik here.

In connection with the announcement that the Nobel Prize in Medicin 2011 goes to Ralph Steinman for his discovery of the dendritic cell and its central role in immune responses, Immunicum is showcased in media (see below) as a promising cancer vaccine company sprung from Steinman's discovery.

- NyTeknik (111012). Read the article here.

- GT (111014). Read the article here.

- BiotechSweden (111111). Read the article here.

- Kemivärlden Biotech (111114). Read the article here .

Immunicum successfully completes a larger toxicity study as, which is an important step towards receiving an approval from the Medical Products Agency to initiate its first clinical trial.

Injection of COMBIG cells into the kidneys of rats did not cause any effects on health status, haematology, clinical chemistry, or histopathology neither acutely, within days after injection, nor after a repeated administration.

Immunicum receives a letter-of-intent from UK-based Cancer Vaccine Institute (CVI), stating that CVI is interested in co-funding and conducting a clinical phase I/II trial in melanoma, using Immunicum's COMBIG-concept. Below, professor Angus Dalgliesh, principal of CVI, expresses his support for Immunicum's vaccine technology:

"We recently met with representatives of Immunicum who presented the COMBIG concept of allo-DC vaccination. Our own experience with allo-vaccines (much of which was done in collaboration with Onyvax Ltd), in the context of whole cell vaccination, has been very convincing. The concept that allo-vaccination with DCs triggers a cascade of immune responses including innate (NK cell activation) and subsequent adaptive, antigen specific responses is interesting and is deserving of further development. We are fully supportive of this work and believe that this allo-DC model may well result in the initiation of anti-tumoural responses where in vitro manipulated autologous DCs have limitations both in terms of GMP manufacture and in their capacity to generate consistent clinical responses. The use of intralesional delivery is of further interest to us and is supported by several recent publications on the intralesional delivery of cellular therapies. Our own clinical experience suggests that such an approach would be of benefit in melanoma and a range of other solid tumours."

The European Patent Office (EPO) notifies Immunicum that it accepts the claims stated in the patent application 03 730 977.0-2406 and intends to grant a patent on the basis of these claims.

The patent covers the use of antigen-presenting-cells, such as DCs, loaded with antigens, for use as an allogeneic vaccine in an MHC-incompatible subject.